Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022

Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Laura Torres-Canchala, Daniela Cleves-Luna, Oriana Arias-Valderrama, Estephania Candelo, María Angelica Guerra, Harry Pachajoa, Manuela Olaya
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	MDPI AG 2022-12-01
Serie:	Children
Ämnen:	adjuvant therapy child adult adult-onset recurrent respiratory papillomatosis juvenile-onset papillomatosis recurrent respiratory papillomatosis systemic bevacizumab treatment
Länkar:	https://www.mdpi.com/2227-9067/10/1/54
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!